Events / Seminars / CLEs

Dr. Weihong Hsing to Speak at Asia-Pacific Pharma Intellectual Property Leader Summit 2019

October 14, 2019

Date and time: Nov. 14 & 15, 2019

Location: Beijing, China

Details: Panitch Schwarze partner Dr. Weihong Hsing will give a presentation on IP due diligence in connection with mergers and acquisitions as part of the 2019 Asia-Pacific Pharma Intellectual Property Leader Summit. Hsing’s session will be held on the second day of the two-day conference in Beijing, China.

The annual summit brings together more than 400 delegates from more than 120 pharmaceutical companies and 40 biotechnology companies to explore the latest trends and topics in the pharmaceutical industry.

As chair of the Life Sciences practice group at Panitch Schwarze Belisario & Nadel, Hsing is a frequent speaker and author. A significant portion of her practice is dedicated to representing large pharmaceutical companies, particularly buyers, involved in mergers and acquisitions. Thorough intellectual property due diligence is a vital part of a successful M&A transaction.

To learn more or to register for the summit, visit the Asia-Pacific Pharma IP Summit website.

About Panitch Schwarze Belisario & Nadel LLPPanitch Schwarze Belisario & Nadel LLP is a boutique intellectual property law firm with offices in Philadelphia and Wilmington, Delaware. The firm’s IP law practitioners provide strategic litigation, licensing and counseling service relating to patents, trademarks, copyrights and trade secrets, domain names and internet issues domestically and internationally. The firm’s long-standing relationships with a network of associates worldwide enable its attorneys and advisors to provide clients with global intellectual property advice and protection.

Contact Us

By checking this box, I agree to the terms and conditions outlined on our Disclaimer page.
Email Disclaimer

Sending an email to our office does not create an attorney-client relationship, and none will be formed unless there is an expressed agreement between the firm and the client. Thus, we strongly advise against sending confidential or privileged information to us until you can establish such a relationship. Furthermore, we advise against sending privileged or confidential information through email at all, since we can in no way ensure the security of your email. In fact, neither this website nor the email system involved is encrypted, so you should not assume that your email is confidential. We cannot guarantee that someone else will not see it.

Do you agree to this Email Disclaimer?

I Agree I Do Not Agree